JP2008523082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523082A5 JP2008523082A5 JP2007545627A JP2007545627A JP2008523082A5 JP 2008523082 A5 JP2008523082 A5 JP 2008523082A5 JP 2007545627 A JP2007545627 A JP 2007545627A JP 2007545627 A JP2007545627 A JP 2007545627A JP 2008523082 A5 JP2008523082 A5 JP 2008523082A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- hydroxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 91
- 229910052739 hydrogen Inorganic materials 0.000 claims 79
- 239000001257 hydrogen Substances 0.000 claims 79
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 71
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 38
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 37
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 35
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 35
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims 34
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims 32
- 125000001475 halogen functional group Chemical group 0.000 claims 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 31
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 30
- 125000004423 acyloxy group Chemical group 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 24
- -1 oxy, thio Chemical group 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 241001465754 Metazoa Species 0.000 claims 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 14
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 14
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 12
- 150000001540 azides Chemical class 0.000 claims 10
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 10
- 229930024421 Adenine Natural products 0.000 claims 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 7
- 229960000643 adenine Drugs 0.000 claims 7
- 229940104302 cytosine Drugs 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229940113082 thymine Drugs 0.000 claims 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 7
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940035893 uracil Drugs 0.000 claims 6
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- KIMCWRBPIXPGPA-LLVKDONJSA-N [[(2r)-3-(1h-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]amino]phosphonic acid Chemical compound C1=CC=C2C(C[C@H](C(=O)NC)NP(O)(O)=O)=CNC2=C1 KIMCWRBPIXPGPA-LLVKDONJSA-N 0.000 claims 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 235000013928 guanylic acid Nutrition 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 125000006301 indolyl methyl group Chemical group 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000005289 uranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63467704P | 2004-12-09 | 2004-12-09 | |
| PCT/US2005/044442 WO2006063149A1 (en) | 2004-12-09 | 2005-12-08 | Nucleosides with antiviral and anticancer activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523082A JP2008523082A (ja) | 2008-07-03 |
| JP2008523082A5 true JP2008523082A5 (enExample) | 2009-01-22 |
Family
ID=36578243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545627A Withdrawn JP2008523082A (ja) | 2004-12-09 | 2005-12-08 | 抗菌活性および抗癌活性を有するヌクレオチド |
Country Status (5)
| Country | Link |
|---|---|
| US (7) | US8399428B2 (enExample) |
| EP (1) | EP1827460A4 (enExample) |
| JP (1) | JP2008523082A (enExample) |
| CA (1) | CA2589935A1 (enExample) |
| WO (1) | WO2006063149A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| JP2008523082A (ja) | 2004-12-09 | 2008-07-03 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗菌活性および抗癌活性を有するヌクレオチド |
| JP2009526850A (ja) | 2006-02-14 | 2009-07-23 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| EP2120565B1 (en) * | 2006-12-20 | 2012-11-28 | Merck Sharp & Dohme Corp. | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| WO2008104408A2 (en) * | 2007-02-27 | 2008-09-04 | K. U. Leuven Research & Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| EA019295B1 (ru) * | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
| TWI498117B (zh) | 2010-03-31 | 2015-09-01 | Gilead Pharmasset Llc | 核苷氨基磷酸酯 |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| US9095599B2 (en) | 2011-01-03 | 2015-08-04 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
| ES2686219T3 (es) | 2011-03-01 | 2018-10-16 | NuCana plc | Compuestos químicos |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| CN103987712B (zh) * | 2011-07-19 | 2016-05-04 | 河南美泰宝生物制药有限公司 | 2’，3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药 |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| SE1450130A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| PL2794627T3 (pl) * | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US20130315868A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| CN104640444B (zh) * | 2012-06-16 | 2016-12-14 | 河南美泰宝生物制药有限公司 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
| WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3027636B1 (en) * | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| PT3224268T (pt) * | 2014-11-28 | 2019-09-04 | NuCana plc | Novos derivados de 3¿-desoxiadenosina com fosforamidatos de ésteres de aminoácidos em 2¿ e/ou 5¿ como compostos anticancerígenos |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| CN107428792B (zh) | 2014-12-15 | 2023-01-24 | 埃默里大学 | 用于治疗乙型肝炎病毒的磷酰胺 |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| WO2016189055A1 (en) * | 2015-05-27 | 2016-12-01 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of cancer |
| CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| BR112018076913A2 (pt) | 2016-06-24 | 2019-04-02 | Emory University | fosforamidatos para o tratamento do vírus da hepatite b |
| CN109689672B (zh) | 2016-09-07 | 2023-05-30 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
| GEP20227457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| WO2019201283A1 (en) | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| US11439656B2 (en) * | 2018-08-30 | 2022-09-13 | Regents Of The University Of Minnesota | Pharmaceutical compounds and uses thereof |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR20240022574A (ko) | 2021-06-17 | 2024-02-20 | 아테아 파마슈티컬즈, 인크. | 유리한 항-hcv 조합 요법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827337D0 (en) | 1988-11-23 | 1988-12-29 | Medical Res Council | Nucleoside analogues |
| US5614504A (en) | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| GB9207381D0 (en) * | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
| EP0690068A4 (en) | 1993-03-18 | 1996-07-31 | Akira Matsuda | NOVEL 2'-METHYLIDENENUCLEOTIDE COMPOUND, PROCESS FOR OBTAINING THIS COMPOUND AND ITS PHARMACEUTICAL USE |
| US6677310B1 (en) | 1999-04-21 | 2004-01-13 | Nabi | Ring-expanded nucleosides and nucleotides |
| US5475985A (en) * | 1993-12-14 | 1995-12-19 | Carrier Corporation | Electronic control of liquid cooled compressor motors |
| US5659023A (en) | 1995-02-01 | 1997-08-19 | Gilead Sciences, Inc. | Nucleotide analogues |
| GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| WO1997021452A2 (en) | 1995-12-14 | 1997-06-19 | Advanced Magnetics, Inc. | Macromolecular prodrugs of nucleotide analogs |
| AU3363499A (en) * | 1998-03-27 | 1999-10-18 | George W. Griesgraber | Nucleosides with antiviral and anticancer activity |
| US6030957A (en) * | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| EP1200455B1 (en) * | 1999-07-22 | 2009-04-22 | Celmed Oncology (USA), Inc. | Enzyme catalyzed therapeutic activation |
| AU784462B2 (en) * | 2000-03-31 | 2006-04-06 | Purdue Research Foundation | Phosphoramidate prodrugs |
| WO2003000713A1 (en) * | 2001-06-21 | 2003-01-03 | Glaxo Group Limited | Nucleoside compounds in hcv |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| AU2005267421B2 (en) | 2004-06-24 | 2010-06-03 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| JP2008517912A (ja) | 2004-10-21 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | ＲＮＡ依存性ＲＮＡウイルス感染治療用フッ素化ピロロ［２，３−ｄ］ピリミジンヌクレオシド |
| JP2008523082A (ja) | 2004-12-09 | 2008-07-03 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗菌活性および抗癌活性を有するヌクレオチド |
| US7964582B2 (en) | 2005-03-21 | 2011-06-21 | J&J Consumer Companies, Inc. | Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers |
| EP1928475B1 (en) | 2005-08-15 | 2018-05-23 | Riboscience LLC | Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides |
| JP2009526850A (ja) | 2006-02-14 | 2009-07-23 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
-
2005
- 2005-12-08 JP JP2007545627A patent/JP2008523082A/ja not_active Withdrawn
- 2005-12-08 US US11/721,325 patent/US8399428B2/en not_active Expired - Fee Related
- 2005-12-08 WO PCT/US2005/044442 patent/WO2006063149A1/en not_active Ceased
- 2005-12-08 CA CA002589935A patent/CA2589935A1/en not_active Abandoned
- 2005-12-08 EP EP05853381A patent/EP1827460A4/en not_active Withdrawn
-
2013
- 2013-01-29 US US13/753,252 patent/US8765935B2/en not_active Expired - Lifetime
-
2014
- 2014-03-28 US US14/229,292 patent/US8815830B2/en not_active Expired - Lifetime
- 2014-07-21 US US14/336,225 patent/US20150025220A1/en not_active Abandoned
-
2016
- 2016-02-16 US US15/044,853 patent/US20160159845A1/en not_active Abandoned
-
2017
- 2017-10-18 US US15/787,140 patent/US20180258131A1/en not_active Abandoned
-
2019
- 2019-02-27 US US16/287,387 patent/US20200095273A1/en not_active Abandoned